AGEN-1571 is under clinical development by Agenus and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AGEN-1571’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AGEN-1571 is under development for the treatment of solid tumors. The drug candidate acts by targeting Ig-like transcript 2 (ILT2) receptor. The drug candidate is being developed based on retrocyte display technology platform. It is administered through intravenous route.
Agenus is a clinical-stage immuno-oncology company that discovers, develops, and commercializes a wide range of immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company’s pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company’s technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. The company collaborates with several pharmaceutical companies such as GSK, Incyte, and Merck. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.
For a complete picture of AGEN-1571’s drug-specific PTSR and LoA scores, buy the report here.